In this study, we have successfully demonstrated the effectiveness of a site-specific Btk gene correction strategy in a Btk/Tec−/− mouse model of XLA, showing significant improvement in B cell development, function, and antibody production. This evidence concerns the gene BTK and Bruton-type agammaglobulinemia.